Alpha¹ by KaimenConfidential

Kaimen Rigor review

Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo.

PALM007 Writing Group, Ali R, Alonga J, Biampata JL, Kombozi Basika M, Maljkovic Berry I, Bisento N, Blum E, Bonnett T, Cone K, Crozier I, Davey R, Dilu A, Dodd LE, Gulati I, Hruby D, Ibanda A, Isse F, Kasareka SS, Kayembe G, Kojan R, Luzolo EK, Lane HC, Lawanga L, Liesenborghs L, Shosongo Lunghe C, Lula Y, Lusakibanza M, Lutete GT, Mbala-Kingebeni P, Miranda A, Mukadi-Bamuleka D, Mukendi G, Lupola PM, Muyembe-Tamfum JJ, Ndungunu R, Nganga B, Ntamabyaliro N, Nussenblatt V, Omulepu I, Omalokoho Onosomba J, Proschan M, Rubenstein K, Saknite I, Schechner A, Shaw-Saliba K, Sivahera B, Smolskis M, Tillman A, Tkaczyk E, Tshimanga C, Tshiani Mbaya O, Tshomba A, Yemba Unda Tshomba F, Vallee D, Vogel S, Weyers S

DOI: 10.1056/NEJMoa2412439
Record issued: 2026-08-10
Engine: 7.29.0
Exported: 2026-09-21

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/5686e0a9-27af-42c8-800a-4e5bbeccaa93 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

Incomplete run — read this verdict with care

Only 2 of 3 reviewers completed. Each verdict below is the majority of 2, not of 3 — the disagreement between reviewers that normally filters out one model's noise could not be applied.
This run hit its time budget: at least one step billed work that never produced a result.

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ReportingKey resources not met−0.5★
ReportingData & code availability not met−0.5★
ReportingBiological variables partially met−0.25★

Model-reported confidence: moderateReviewer agreement: moderateEngine: 7.29.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Biggest issues

01Key resources not identified
highDisclosurereviewer-assessedFull detail
The PCR kit is identified, but the investigational product (tecovirimat) is not fully described (manufacturer, formulation, strength, dose regimen) and statistical software is not named.
“At each site, MPXV nucleic acid was detected using the RADI platform (KH Medical) MPOX Detection Kit”
MethodsFind in source
02Data and code not shared
highDisclosurereviewer-assessedFull detail
No data availability statement, repository deposit, accession numbers, or code sharing are mentioned in the manuscript.

Findings by category

01ArithmeticNone found 102OverreachOverstated conclusions · partly checked 103AuthenticityData authenticity concerns 304DisclosureReporting gaps · partly checked 05AvailabilityNone found 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper reports a well-conducted double-blind RCT of tecovirimat for clade I mpox, with strong design, ethical approvals, and transparent reporting of null results. The main weaknesses are missing data availability statement, incomplete identification of key resources (statistical software and tecovirimat formulation), and a missing baseline weight variable.

Two independent review runs of the same model (DeepSeek V4) were synthesized; the copies converged on most dimensions but diverged on biological variables (weight reporting) and key resources (tecovirimat details). The copyedit pass flagged minor issues. No retracted or non-existent references were found. The statistics recomputation was limited to 1 test and was consistent.

Numerical inconsistencies

None found

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Checked — nothing surfaced.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p = .140 · recomputed p = .111Reviewer 1
Primary endpoint crHR 1.13 with 95% CI 0.97–1.31 maps to a two-sided Wald p of about 0.11, slightly below the reported Gray's-test p of 0.14.
“The stratified crHR for days to lesion resolution was 1.13 (95% confidence interval [CI] 0.97 to 1.31; p=0.14)”
Find in source
Taken as given: the crHR is a Fine-Gray subdistribution hazard ratio reported with a two-sided 95% CI, so SE=(log(1.31)−log(0.97))/(2×1.96); the reported p=0.14 comes from Gray's test, which is not identical to the Wald test on the crHR, so a small difference is expected and is not an error
Method: Two-sided p from log-scale estimate and 95% CI (Wald approximation) via pCI(estimate, low, high, log=1); compared to the reported Gray's-test p.
How we recomputed it: pCI(1.13, 0.97, 1.31, 1)

Overstated conclusions

1 finding · worst low

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

partialReviewer 2
The level of care provided in PALM007 likely improved outcomes.
The paper compares observed mortality (1.7%) to historical case-fatality rate (4.6%), but this is a post-hoc comparison and not a controlled analysis; it is plausible but not proven.
Evidence: Mortality 1.7% vs 4.6% case-fatality rate from DRC surveillance.
“While the level of care provided in PALM007 likely improved outcomes, it may not be easily provided in resource-limited and outpatient settings.”
DiscussionFind in source
supportedReviewers 1, 2
Tecovirimat did not improve days to lesion resolution in Clade I MPXV infected individuals.
The primary crHR of 1.13 (95% CI 0.97–1.31, p=0.14) and median 7 vs 8 days directly support a null primary finding.
Evidence: Stratified crHR 1.13 (0.97–1.31; p=0.14); median 7 vs 8 days.
“Tecovirimat did not improve days to lesion resolution in Clade I MPXV infected individuals.”
ConclusionFind in source
supportedReviewers 1, 2
No safety concerns were identified with tecovirimat.
Comparable SAE (5.1% vs 5.0%) and AE (72.9% vs 70.5%) rates across arms support the safety claim.
Evidence: SAEs 5.1% vs 5.0%; AEs 72.9% vs 70.5%.
“No safety concerns were identified.”
AbstractFind in source
supportedReviewer 1
Tecovirimat did not improve declines in viremia (PCR-negativity).
PCR-negativity at 14 days was similar across blood, lesion, and oropharyngeal samples in both arms, supporting no treatment-related virologic effect.
Evidence: At 14 days, PCR-negativity in blood, lesion and oropharyngeal samples were similar in both treatment arms.
“No treatment differences were observed with any sample type (blood, lesion, or oropharynx).”
AbstractFind in source
supportedReviewer 1
A pre-specified subgroup analysis suggested faster lesion resolution in Kole, but this was not a robust treatment effect.
The paper transparently reports the Kole finding as exploratory, explains it via baseline severity asymmetry, and shows adjusted models eliminated the interaction, so the claim as hedged is supported.
Evidence: Site interaction HR=1.59 (1.15–2.21); adjusted models showed no interaction; virologic endpoints showed no independent enhanced clearance.
“Models that adjusted for baseline imbalances in lesion count and blood, OP and skin PCR cycle-thresholds (CT) were explored. With these adjustments, no interaction of treatment effect with site was observed.”
DiscussionFind in source
supportedReviewer 2
Our study highlights the importance of conducting clinical trials of investigational treatments during outbreaks.
The trial successfully conducted a randomized controlled trial during an outbreak, providing evidence for tecovirimat, which had been used without such evidence.
Evidence: The trial design and execution are described; the conclusion is directly supported by the fact that the study was conducted during an outbreak and provided definitive evidence.
“Our study highlights the importance of conducting clinical trials of investigational treatments during outbreaks including studies of products that may have been licensed in the absence of such studies.”
DiscussionFind in source

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Methods and results do not matchAssessed

1 integrity concern flagged (0 high).

lowmethod result mismatch
The reported primary p=0.14 (Gray's test) corresponds to a Wald-transformed CI p of about 0.11. This is plausibly explained by the difference between Gray's test and the Wald test on the subdistribution hazard ratio, so it is a mild note rather than evidence of error.
“The stratified crHR for days to lesion resolution was 1.13 (95% confidence interval [CI] 0.97 to 1.31; p=0.14)”
ResultsFind in source

Reporting gaps

3 findings · worst high

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed
Key resources not identifiedAssessed
Biological variables underreported (sex, age, strain)Assessed

Eight Dimensions5 pass · 1 warn · 2 fail

The Background cites non-human primate efficacy models, healthy-volunteer safety studies, prior smallpox antiviral development, and the clade IIb outbreak/PHEIC context, and explicitly states that RCT evidence in mpox patients is lacking. The rationale linking this gap to the PALM007 objectives is explicit, and the prior limitations (efficacy unknown, dosing 'established from animal models and concentrations in healthy human volunteers') are acknowledged and addressed by the trial design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The premise is well established: tecovirimat's mechanism, animal efficacy, and safety profile are cited, and the absence of RCT evidence in mpox patients is the clear rationale.

Evidence

“Evidence from randomized controlled trials demonstrating safety and efficacy in mpox patients is lacking.”

IntroductionFind in source

“Tecovirimat, originally developed as an antiviral against smallpox, is an oral orthopoxvirus-selective antiviral with activity against MPXV in non-human primate models”

IntroductionFind in source

“Here, we report results from a randomized controlled trial of the safety and efficacy of tecovirimat for mpox (clade I MPXV) in Congolese patients in a region with endemic disease.”

IntroductionFind in source

PASSReviewer 2· 95% conf

The paper adequately cites prior research, establishes a logical rationale, and addresses limitations of prior work.

Evidence

“Tecovirimat, originally developed as an antiviral against smallpox, is an oral orthopoxvirus-selective antiviral with activity against MPXV in non-human primate models and is being globally evaluated as a potential therapeutic for mpox”

Introduction ¶1Find in source

“Evidence from randomized controlled trials demonstrating safety and efficacy in mpox patients is lacking.”

Introduction ¶3Find in source

paraphrase[Introduction, paragraph 4]

“The paper states that while tecovirimat is approved in Europe and available in the US, its efficacy in mpox remains unknown, justifying the need for the current RCT.”

The paper describes online randomization stratified by symptom onset and site, double-blind design with unblinded pharmacists, an a priori power calculation, and pre-specified eligibility criteria. The analysis population is ITT, and missing data methods are described.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Core design elements for a human RCT are well-reported: randomization method and stratification, double-blind masking, a priori power calculation, and pre-specified eligibility criteria.

Evidence

“Enrolled patients were randomized (1:1), stratified by days from onset of symptoms (≤7 days vs >7 days) and study site.”

MethodsFind in source

“To detect a 40% improvement in lesion-resolution rate, 318 resolution events were needed for 85% power and 5% two-sided type-I error.”

Statistical analysisFind in source

“The primary analysis was based on the intent-to-treat population”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The study design is rigorous with clear randomization, blinding, power analysis, and inclusion/exclusion criteria.

Evidence

“Randomization was conducted online with secure envelopes available as a backup for internet outages.”

MethodsFind in source

“PALM007 was a double-blind, randomized controlled trial”

MethodsFind in source

“To detect a 40% improvement in lesion-resolution rate, 318 resolution events were needed for 85% power and 5% two-sided type-I error.”

Statistical analysisFind in source

Table 1 reports sex distribution and age, but weight is not included in the baseline table. Health status is reported through malnutrition, HIV, and other comorbidities. Race/ethnicity is only implied as 'Congolese' without specific categories.

Sub-criteria

demographicsINADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthINADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Sex, age, weight, health status, and comorbidities are comprehensively reported in text and Table 1; both sexes were enrolled so no single-sex justification is required.

Evidence

“At baseline, most patients were <18 years old (64.3%); 48.9% were female.”

ResultsFind in source

“Female sex, no. (%) | 141 (47.8) | 151 (50.0)”

Table 1Find in source

“Moderate or severe malnutrition was recorded in 18.6% of cases.”

ResultsFind in source

WARNReviewer 2· 70% conf

Sex and age are reported, but weight is missing from baseline demographics and race/ethnicity is not detailed.

Evidence

paraphrase[Table 1]

“Female sex, no. (%): 141 (47.8) for tecovirimat, 151 (50.0) for placebo.”

paraphrase[Table 1]

“Age (years): median (Q1, Q3): 13.0 (5.0, 24.0) for tecovirimat, 10.0 (5.0, 23.0) for placebo.”

absence[Table 1 and Methods]

Weight not reported in baseline table

The trial was approved by the named ethics committee of the Public Health School, University of Kinshasa, and authorized by the Congolese regulatory authority (ACOREP). Written informed consent and pediatric assent are described. Compliance with ICH GCP-E6 is stated. All applicable human-research ethics criteria are satisfied.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval from a named body, written informed consent with pediatric assent, and ICH-GCP compliance are all explicitly stated.

Evidence

“The trial was approved by the ethics committee of the Public Health School, University of Kinshasa and authorized by the Congolese Pharmaceutical Regulatory Authority (ACOREP).”

MethodsFind in source

“All patients provided written informed consent. Assent was obtained from children aged 12 to 17 years, as required in the DRC.”

MethodsFind in source

“The protocol was conducted in compliance with ICH GCP-E6.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval by a named committee, informed consent description, and regulatory compliance statement are all present.

Evidence

“The trial was approved by the ethics committee of the Public Health School, University of Kinshasa and authorized by the Congolese Pharmaceutical Regulatory Authority (ACOREP).”

MethodsFind in source

“All patients provided written informed consent. Assent was obtained from children aged 12 to 17 years, as required in the DRC.”

MethodsFind in source

“The protocol was conducted in compliance with ICH GCP-E6.”

MethodsFind in source

The MPOX Detection Kit (KH Medical) is adequately identified. However, tecovirimat is only named with manufacturer (SIGA) but without formulation/strength details. The paper references 'see Protocol' for dosing. Additionally, no statistical software is identified for the analysis.

Sub-criteria

mycoplasma testingN/A

reagents identifiedINADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 70% conf

The investigational product (tecovirimat) is adequately identified with source and regimen, but the statistical software is not named.

Evidence

“SIGA provided donations of tecovirimat and placebo pills for the study.”

FundingFind in source

“Tecovirimat dosing was weight-based per investigator brochure”

MethodsFind in source

absence[Methods, Statistical Analysis]

Statistical software not identified.

FAILReviewer 2· 70% conf

The PCR kit is identified, but the investigational product (tecovirimat) is not fully described (manufacturer, formulation, strength, dose regimen) and statistical software is not named.

Evidence

“At each site, MPXV nucleic acid was detected using the RADI platform (KH Medical) MPOX Detection Kit”

MethodsFind in source

paraphrase[Methods, Design]

“Tecovirimat is mentioned as an oral antiviral, but its formulation, strength, and exact dosing are not provided; dosing is per investigator brochure (see Protocol).”

absence[Methods, Statistical Analysis]

Statistical software not identified

The primary analysis uses Fine-Gray and Cox models with exact p-values and 95% CIs. Kaplan-Meier curves and tables are presented. Assumption checking for proportional hazards is not reported, and the software used is not named. No mathematical implausibilities were detected.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedINADEQUATE

mathematical plausibilityPASS

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Statistical methods are named and appropriate, effect estimates are reported with CIs, exact p-values are given, and the reported proportions are arithmetically sound; only software identification is missing.

Evidence

“The stratified crHR for days to lesion resolution was 1.13 (95% confidence interval [CI] 0.97 to 1.31; p=0.14)”

ResultsFind in source

“based on Gray’s test of the competing-risk (“subdistribution”) hazard ratio (crHR)”

Statistical analysisFind in source

absence[Methods, Statistical Analysis]

Statistical software not identified.

PASSReviewer 2· 85% conf

Statistical tests are named, exact p-values and effect sizes with CIs are reported, data presentation is appropriate, and no arithmetical errors are evident. However, assumptions are not verified and statistical software is not identified.

Evidence

“The primary analysis was based on the intent-to-treat population, evaluating differences in days to lesion resolution, based on Gray’s test of the competing-risk (“subdistribution”) hazard ratio (crHR)”

Statistical analysisFind in source

“The stratified crHR for days to lesion resolution was 1.13 (95% confidence interval [CI] 0.97 to 1.31; p=0.14)”

ResultsFind in source

absence[Methods, Statistical Analysis]

Assumptions not verified

The paper does not include any statement about data availability, nor does it mention deposition of data in a public repository or sharing of analysis code. The only link provided is to the trial protocol.

Sub-criteria

code sharingNOT REPORTED

accession numbersNOT REPORTED

repository depositNOT REPORTED

data availability statementNOT REPORTED

Per reviewer (2) — the votes behind the verdict

FAILReviewer 1· 60% conf

No data availability statement is present for this clinical trial, which is a required element; only the protocol and publisher's version are referenced.

Evidence

“Full details of study design can be seen in the protocol at nejm.org (https://nejm.org)”

MethodsFind in source

absence[End of manuscript (Funding section)]

No data availability statement found.

FAILReviewer 2· 95% conf

No data availability statement, repository deposit, accession numbers, or code sharing are mentioned in the manuscript.

Evidence

absence[All sections]

No data availability statement

absence[All sections]

No repository deposit

absence[All sections]

No code sharing

The paper includes a detailed methods section, registration number, reports primary and secondary outcomes including negative results, discusses limitations, and draws conclusions consistent with the evidence. Missing: reference to CONSORT or other reporting guideline, and a separate COI statement (though funding sources are disclosed).

Sub-criteria

funding coiNOT REPORTED

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Methods are detailed, the trial is registered, limitations are thoroughly discussed, and conclusions are proportional; a CONSORT statement and explicit COI declaration are not present.

Evidence

“Trial registration: ClinicalTrials.gov (http://Clinicaltrials.gov) NCT05559099”

FundingFind in source

“Among the limitations is the subjectivity of the primary endpoint.”

DiscussionFind in source

“Tecovirimat did not improve days to lesion resolution in Clade I MPXV infected individuals.”

ConclusionFind in source

PASSReviewer 2· 85% conf

Methods are complete, trial registration is provided, all outcomes are reported, limitations are discussed, and conclusions are proportional. However, a reporting guideline is not referenced and a conflict of interest statement is not explicitly included.

Evidence

paraphrase[Funding statement]

“Trial registration: ClinicalTrials.gov NCT05559099”

“Among the limitations is the subjectivity of the primary endpoint.”

DiscussionFind in source

absence[Methods]

No reporting guideline mentioned

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

ClinicalTrials.gov

NCT05559099

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 17 references by DOI: 8 verified — 9 no DOI (shown, not verified).

NO DOI
Smallpox and its eradication
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Multi-country outbreak of mpox, external situation report #31
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Mpox (monkeypox) outbreak 2022
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Mpox in the Democratic Republic of the Congo: Analysis of National Epidemiological and Laboratory Surveillance Data, 2010 – 2023
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
WHO PHEIC declaration 2024
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
https://cdn.who.int/media/docs/default-source/blue-print/day-1_jean-jacques-muyembe_drc_monkeypox-meeting_02june2022.pdf?sfvrsn=d133676a_3
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Clinical Pharmacology and Biopharmaceutics Review(s) of Tecovirimat
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A proportional hazards model for the subdistribution of a competing risk
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Pharmacokinetics of tecovirimat in persons with mpox: results from ACTG
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

3 data/code links checked; 1 live.

datahttps://clinicaltrials.gov/ct2/show/NCT05559099LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://www.nejm.org/doi/full/10.1056/NEJMoa2412439UNVERIFIEDHTTP 403
Liveness indeterminate — content not checked.
datahttps://nejm.orgUNVERIFIEDHTTP 403
Liveness indeterminate — content not checked.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly punctuation, consistency, other.

MINORpunctuationResults
“range:1,10264”
→ range: 1, 10264 (or 1–10,264)
Run-on punctuation obscures the lesion-count range.
MINORconsistencyDiscussion
“Approximately 50% of nasopharyngeal MPXV PCRs remained positive at 14 days”
→ oropharyngeal
Methods/Table use 'oropharynx'/'OP swab'; Discussion uses 'nasopharyngeal'.
MINORpunctuationAbstract, Results
“crHRs:1.16 (95% CI:0.98 to 1.37)”
→ crHRs: 1.16 (95% CI: 0.98 to 1.37)
Inconsistent colon spacing in several CI/statistic phrases.
MINORotherTitle section
“pmc 1 Placebo-Controlled Trial of Tecovirimat for Endemic (Clade I MPXV) mpox, DRC”
→ Remove 'pmc 1' stray text at the beginning.
Possible metadata artifact from PMC submission.
MINORpunctuationAbstract
“Methods We conducted...”
→ Add a line break or period after 'Methods' for clarity.
Abstract sections lack clear separation.
MINORconsistencyResults
“SAEs and AEs were reported in 5.1% and 72.9% of patients receiving tecovirimat, respectively, compared to 5.0% and 70.5% on placebo.”
→ Consider rephrasing to improve clarity: 'SAEs occurred in 5.1% of tecovirimat patients and 5.0% of placebo patients; AEs occurred in 72.9% and 70.5%, respectively.'
Minor readability issue.

Kaimen Rigor Action ItemsFinal pass before journal submission

This is a post-publication audit. The published study is methodologically robust with no threats to validity. An informed reader should note that the data availability statement is missing, the statistical software is not named, and baseline weight is not reported — these are reporting gaps, not errors, and do not warrant a correction. The authors should consider adding a data availability statement and a COI statement in any future version or correction.

1.
HIGHdata code
Add a data availability statement specifying a managed-access route for de-identified trial data (e.g., via a data access committee or platform with conditions/timeframe) in a new 'Data Availability' section near the Funding statement.
A data availability statement is a required element for a data-driven clinical trial; its absence is a major reporting gap that readers and journals would expect.
2.
HIGHreporting
Add a formal Conflicts of Interest declaration (even if 'all authors declare no competing interests' plus the SIGA relationship) alongside the funding statement.
A separate COI declaration is standard for clinical trials and ensures transparency regarding potential financial interests.
3.
HIGHrigor
Name the statistical software and version used for all analyses (Fine-Gray, Cox, Kaplan-Meier) in the Statistical Analysis section.
Reproducibility requires knowing the software and version used; this is a common reporting requirement.
4.
HIGHrigor
Provide full identification of tecovirimat: include manufacturer, formulation, strength (e.g., 200 mg capsules), and the exact dose regimen in the Methods, not only a reference to the protocol.
The investigational product should be fully described in the manuscript for transparency and reproducibility.
5.
MEDIUMreporting
Include weight in the baseline demographics table (Table 1) as a key variable, especially since dosing is weight-based.
Weight is a fundamental baseline characteristic and its absence is a notable omission for a trial with weight-based dosing.
6.
MEDIUMreporting
Add an explicit statement that the trial follows CONSORT reporting guidelines and provide a completed CONSORT checklist as supplementary material.
Referencing the CONSORT guideline is standard for RCTs and improves reporting transparency.
7.
MEDIUMstatistics
Report the verification of the proportional hazards assumption for the Cox model and the Fine-Gray model (e.g., using Schoenfeld residuals) in the Statistical Analysis section.
Assumption checking is a standard part of survival analysis and its absence leaves a minor gap in the analysis quality.
8.
LOWcopyedit
Fix the run-on punctuation in the lesion-count range 'range:1,10264' to a clear range (e.g., 'range: 1–10,264') in the Results.
Correct formatting improves readability and avoids confusion.
9.
LOWcopyedit
Correct the inconsistency between 'nasopharyngeal' and 'oropharyngeal' swab terms in the Discussion (the Methods/Table use 'oropharynx') to maintain consistency.
Consistent terminology is essential for scientific accuracy.
10.
LOWcopyedit
Remove the stray 'pmc 1' text at the beginning of the title.
This appears to be a metadata artifact and should be cleaned for the final version.
11.
LOWcopyedit
Add line breaks or periods after section headers in the Abstract (e.g., 'Methods' should be followed by a period or line break) for clarity.
Improves readability of the structured abstract.
12.
LOWcopyedit
Rephrase the SAE/AE sentence in the Results to improve clarity, e.g., 'SAEs occurred in 5.1% of tecovirimat patients and 5.0% of placebo patients; AEs occurred in 72.9% and 70.5%, respectively.'
Minor readability improvement.

Full text (36,632 chars)Analyzed: Aug 10, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo.

DOI

10.1056/NEJMoa2412439

Record issued

2026-08-10

Engine

7.29.0

Exported

2026-09-21